Literature DB >> 19407927

Metabolism and pharmacokinetics in rats of ganoderiol F, a highly cytotoxic and antitumor triterpene from Ganoderma lucidum.

Qun Zhang1, Feng Zuo, Norio Nakamura, Chao-Mei Ma, Masao Hattori.   

Abstract

The metabolism of ganoderiol F (GF), a cytotoxic and antitumor triterpene from Ganoderma lucidum, by intestinal bacteria and its pharmacokinetics in rats were investigated by using liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS). GF was converted to ganodermatriol by anaerobic incubation with bacterial mixtures from rats and humans. This metabolite was detected in rat feces, but not in plasma and urine, after oral administration of GF. The fate of GF after oral (p.o.) and intravenous (i.v.) administration to rats was examined in pharmacokinetics studies. Plasma samples pretreated by solid-phase extraction were quantified by HPLC/MS/MS over a GF concentration range of 1.25-100 ng/ml (S/N = 5). The intra- and interday precision (CV%) was below 8% and accuracy was within the range of 95.9-103.6% for all samples. The range of recovery ratios was 89.2-98.2%. After the administration of GF at 0.5 mg/kg i.v., the plasma concentrations of GF quickly declined and the elimination half-life values (t(1/2alpha) and t(1/2beta)) were about 2.4 and 34.8 min. On the other hand, the elimination half-life values (t(1/2alpha)) after p.o. administration of GF at doses of 20 and 50 mg/kg were 14.4 and 143.3 min for the former, and 18.6 and 114.6 min for the latter. The AUC(0-t) value was 11.17 (ng/ml) h at a GF dose of 0.5 mg/kg i.v., but 49.4 and 111.6 (ng/ml) h at GF doses of 20 and 50 mg/kg p.o., respectively, indicating that the AUC(0-t) value is proportional to the administered oral doses. The estimated absolute bioavailability of GF in rats was F = 0.105.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19407927     DOI: 10.1007/s11418-009-0337-5

Source DB:  PubMed          Journal:  J Nat Med        ISSN: 1340-3443            Impact factor:   2.343


  14 in total

1.  The biologically active constituents of Ganoderma lucidum (Fr.) Karst. Histamine release-inhibitory triterpenes.

Authors:  H Kohda; W Tokumoto; K Sakamoto; M Fujii; Y Hirai; K Yamasaki; Y Komoda; H Nakamura; S Ishihara; M Uchida
Journal:  Chem Pharm Bull (Tokyo)       Date:  1985-04       Impact factor: 1.645

2.  Anti-HIV-1 and anti-HIV-1-protease substances from Ganoderma lucidum.

Authors:  S el-Mekkawy; M R Meselhy; N Nakamura; Y Tezuka; M Hattori; N Kakiuchi; K Shimotohno; T Kawahata; T Otake
Journal:  Phytochemistry       Date:  1998-11       Impact factor: 4.072

3.  Seven New Triterpenes from Ganoderma lucidum.

Authors:  L J Lin; M S Shiao; S F Yeh
Journal:  J Nat Prod       Date:  1988-09       Impact factor: 4.050

4.  Angiotensin converting enzyme-inhibitory triterpenes from Ganoderma lucidum.

Authors:  A Morigiwa; K Kitabatake; Y Fujimoto; N Ikekawa
Journal:  Chem Pharm Bull (Tokyo)       Date:  1986-07       Impact factor: 1.645

5.  Effects of the extracts of Ganoderma lucidum on blood glucose level in rats.

Authors:  Y Kimura; H Okuda; S Arichi
Journal:  Planta Med       Date:  1988-08       Impact factor: 3.352

6.  Cardiovascular effects of mycelium extract of Ganoderma lucidum: inhibition of sympathetic outflow as a mechanism of its hypotensive action.

Authors:  S Y Lee; H M Rhee
Journal:  Chem Pharm Bull (Tokyo)       Date:  1990-05       Impact factor: 1.645

7.  Antifibrotic effects of a polysaccharide extracted from Ganoderma lucidum, glycyrrhizin, and pentoxifylline in rats with cirrhosis induced by biliary obstruction.

Authors:  E J Park; G Ko; J Kim; D H Sohn
Journal:  Biol Pharm Bull       Date:  1997-04       Impact factor: 2.233

8.  New triterpene aldehydes, lucialdehydes A-C, from Ganoderma lucidum and their cytotoxicity against murine and human tumor cells.

Authors:  Jiang-Jing Gao; Byung-Sun Min; Eun-Mi Ahn; Norio Nakamura; Hyeong-Kyu Lee; Masao Hattori
Journal:  Chem Pharm Bull (Tokyo)       Date:  2002-06       Impact factor: 1.645

9.  Solution properties of antitumor sulfated derivative of alpha-(1-->3)-D-glucan from Ganoderma lucidum.

Authors:  L Zhang; M Zhang; Q Zhou; J Chen; F Zeng
Journal:  Biosci Biotechnol Biochem       Date:  2000-10       Impact factor: 2.043

10.  Mechanisms of hypoglycemic activity of ganoderan B: a glycan of Ganoderma lucidum fruit bodies.

Authors:  H Hikino; M Ishiyama; Y Suzuki; C Konno
Journal:  Planta Med       Date:  1989-10       Impact factor: 3.352

View more
  2 in total

1.  Systems biology of meridians, acupoints, and chinese herbs in disease.

Authors:  Li-Ling Lin; Ya-Hui Wang; Chi-Yu Lai; Chan-Lao Chau; Guan-Chin Su; Chun-Yi Yang; Shu-Ying Lou; Szu-Kai Chen; Kuan-Hao Hsu; Yen-Ling Lai; Wei-Ming Wu; Jian-Long Huang; Chih-Hsin Liao; Hsueh-Fen Juan
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-18       Impact factor: 2.629

2.  Pharmacokinetics of ganoderic acids a and f after oral administration of ling zhi preparation in healthy male volunteers.

Authors:  Supanimit Teekachunhatean; Sasinun Sadja; Chadarat Ampasavate; Natthakarn Chiranthanut; Noppamas Rojanasthien; Chaichan Sangdee
Journal:  Evid Based Complement Alternat Med       Date:  2012-04-22       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.